# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-052056
Filing Date
2024-05-02
Accepted
2024-05-02 16:03:50
Documents
69
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | aldx-20240331.htm iXBRL | 10-Q | 1609565
2 | EX-31.1 | aldx-ex31_1.htm | EX-31.1 | 15497
3 | EX-31.2 | aldx-ex31_2.htm | EX-31.2 | 15785
4 | EX-32.1 | aldx-ex32_1.htm | EX-32.1 | 11602
5 | GRAPHIC | img130884783_0.jpg | GRAPHIC | 77075
| Complete submission text file | 0000950170-24-052056.txt |  | 6433735

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | aldx-20240331.xsd | EX-101.SCH | 937511
72 | EXTRACTED XBRL INSTANCE DOCUMENT | aldx-20240331_htm.xml | XML | 920919

Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 24908053
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)